In neuroblastoma clinical samples, research conducted by Yu et al. corroborated that patients with low RUNX3 expression exhibited significantly reduced survival rates, whereas higher levels of RUNX3 expression were frequently observed in patients at favorable stages 1 and 2 [114]. The gene discussed is RUNX3; the disease is neuroblastoma.